Needham & Company, a privately held, full-service investment bank, announced that Mike Matson recently joined the Firm as a Senior Research Analyst covering Medical Technologies & Diagnostics. He will be based in the Firm's New York office.
Prior to joining Needham, Matson spent nine years covering the medical supplies and devices industry for Mizuho Securities and Wells Fargo Securities. He also previously worked in the medical device industry for Stryker's Orthopedics and Endoscopy divisions in marketing and product development. Matson was ranked first for earnings estimating in the medical device industry in the 2013 FT/ StarMine World's Top Analysts survey, second for stock picking in the medical device industry in the 2008 FT/StarMine World's Top Analysts survey, and fourth in the medical device industry for stock picking in the 2007 Wall Street Journal's Best on the Street.
"Mike's expertise will add another important dimension to our Healthcare Research Group," said Tom Maloney, Director of Research. "We think medical device and diagnostics companies are an important growth area in the healthcare space, and Mike's outstanding reputation gives us increased visibility and credibility in the space." To date, Mike has rolled out coverage on several companies including C.R. Bard, Inc. (BCR), CONMED Corp. (CNMD), Covidien plc (COV), MAKO Surgical Corp. (MAKO), Nuvasive, Inc. (NUVA), ResMed Inc. (RMD), Stryker Corp. (SYK), Wright Medical Group, Inc. (WMGI) and Zimmer Holdings, Inc. (ZMH).
Mike is a CFA charterholder and holds a medical device patent (U.S. patent 6,919,914).
Needham & Company, a subsidiary of The Needham Group, Inc., is a privately held, full-service investment bank that has focused exclusively on growth companies since it was founded 28 years ago.
((Comments on this story may be sent to firstname.lastname@example.org))